Abstracts tagged "neurology"

Abstract Number: 2049 • ACR Convergence 2025
Descriptive Analysis of a Cohort of Neurosarcoidosis Mimics
Shivani Rangaswamy¹, Andrea Lopez¹, Megumi Sugita¹, Ethan Eyman¹, Elijah Lackey¹ and Jeffrey Shen², ¹Duke University Hospital, Durham, ²Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham, NC
Background/Purpose: Sarcoidosis is a granulomatous multi-system disease with nervous system involvement in 5-20% of patients. Diagnosis of neurosarcoidosis is challenging due to its broad spectrum…
Abstract Number: 2025 • ACR Convergence 2025
Spectrum of Autoantibodies in CNS Demyelinating Diseases: Clinical, Laboratory and Imaging Associations
Anna Rapti¹, Dimitris Karathanasis², Sylvia Raftopoulou¹, Charalampos Skarlis¹, Clio Mavragani¹ and Maria Eleftheria Evangelopoulos², ¹Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²First Department of Neurology, School of Medicine, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece
Background/Purpose: Systemic autoimmune diseases (SADs) may present with CNS demyelination, mimicking multiple sclerosis (MS), though driven by distinct immunopathogenic mechanisms. While ANA and aPL are…
Abstract Number: 1682 • ACR Convergence 2025
Sjögren’s Disease Salivary Gland Fibroblast Subsets are Proinflammatory and Aberrantly Promote Pain
Sara McCoy¹, Rachael Bogle², michele larsen³, Li Chen⁴, thomas pranzatelli⁵, Paola Perez⁶, john chiorini⁷, Alan Baer⁸, A. Darise Farris⁹, Christopher Lessard⁹, Astrid Rasmussen⁹, Caroline Shiboski¹⁰, Stephen Shiboski¹⁰, Alexander Mikesell³, Zachary Campbell³, Alex Tsoi², Johann Gudjonsson¹¹ and Blake M. Warner¹², ¹University of Wisconsin–Madison, Madison, WI, ²University of Michigan, Holland, OH, ³University of Wisconsin, Madison, ⁴University of Michigan, Ann Arbor, ⁵NIH, Bethesda, ⁶NIDCR, Bethesda, MD, ⁷NIH, bethesda, MD, ⁸Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰University of California San Francisco, San Francisco, CA, ¹¹University of Michigan, Ann Arbor, MI, ¹²National Institutes of Health, Bethesda, MD
Background/Purpose: Fibroblasts (fb) are increasingly recognized as dynamic signaling hubs in rheumatic disease, yet their contribution to Sjögren Disease (SjD) remains poorly defined. We dissect…
Abstract Number: 1591 • ACR Convergence 2025
Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis
Zsuzsanna McMahan¹, Claudia Pedroza², Katie Lee³, Bingrui Chen³, Ami Shah⁴, Jody Hooper⁵, Srinivas Puttapaka⁶, Livia Casciola-Rosen⁷ and Subhash Kulkarni⁸, ¹UT Health Houston, Houston, TX, ²UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ³UTHealth Houston, Houston, TX, ⁴Johns Hopkins Rheumatology, Baltimore, MD, ⁵Stanford University, Stanford, CA, ⁶BIDMC/Harvard, Boston, MA, ⁷Johns Hopkins University, Baltimore, MD, ⁸BIDMC, Boston, MA
Background/Purpose: Gastrointestinal (GI) dysfunction is common and often debilitating in systemic sclerosis (SSc). Though it affects most patients, mechanisms are poorly understood and biomarkers for…
Abstract Number: 1384 • ACR Convergence 2025
Systematic Review of Therapies for Central Nervous System Manifestations in Sjögren’s Disease
Ghaith Noaiseh¹, Arun Varadhachary², Katherine Hammitt³, Julie Frantsve-Hawley³, Paula Barreras Cortes⁴, Shamik Bhattacharyya⁵, E. Sherwood Brown⁶, Drew Carey⁷, Robert Fox⁸, Brent Goodman⁹, Thomas Grader-Beck¹⁰, Janet Lewis¹¹, Stephen Maitz¹², Steven Mandel¹³, Jenifer McCombe¹⁴, Astrid Rasmussen¹⁵, George Sarka¹⁶, Daniel Wallace¹⁷, Frederick Vivino¹⁸, Rochelle Zak¹⁹, Nancy Carteron²⁰, R Hal Scofield¹⁵ and Steven Carsons²¹, ¹University of Kansas Medical Center, Kansas City, KS, ²Washington University in St. Louis, St. Louis, MO, ³Sjogren's Foundation, Reston, VA, ⁴Cedars Sinai, Los Angeles, CA, ⁵Brigham and Women's Hospital, Malden, MA, ⁶UT Southwestern Medical Center, Dallas, TX, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Rheumatology Clinic, San Diego, CA, ⁹HonorHealth, Scottsdale, AZ, ¹⁰Johns Hopkins, Reisterstown, MD, ¹¹University of Virginia, Charlottesville, VA, ¹²U.S. Department of Veterans Affairs, Coatesville, PA, ¹³Donald and Barbara Zucker School of Medicine and Hofstra/Northwell, Hempstead, NY, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Cedars-Sinai Medical Center, Laguna Hills, CA, ¹⁷Cedars Sinai Medical Center, Studio City, CA, ¹⁸University of Pennsylvania, Bryn Mawr, PA, ¹⁹UCSF Health, San Francisco, CA, ²⁰University of California, Berkeley & San Francisco, Angwin, CA, ²¹NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Sjögren’s disease is recognized as a multifaceted autoimmune disease impacting almost any organ or body system. Of particular importance is the central nervous system…
Abstract Number: 1380 • ACR Convergence 2025
Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Beatrice Dei¹, Stefano Donati¹, Gaetano La Rocca², Giovanni Fulvio¹, Federico Fattorini¹, Antonello Sulis¹, Michele Moretti¹, Elena Elefante¹, Francesco Ferro³, Giulia Ricci⁴, Marta Mosca⁵ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Neurology Unit, University of Pisa, Pisa, Toscana, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…
Abstract Number: 1378 • ACR Convergence 2025
Prevalence of Central Nervous System Manifestations in Sjögren’s Disease
Arun Varadhachary¹, Ghaith Noaiseh², Katherine Hammitt³, Julie Frantsve-Hawley³, Paula Barreras Cortes⁴, Shamik Bhattacharyya⁵, E. Sherwood Brown⁶, Drew Carey⁷, Robert Fox⁸, Brent Goodman⁹, Thomas Grader-Beck¹⁰, Janet Lewis¹¹, Stephen Maitz¹², Steven Mandel¹³, Jenifer McCombe¹⁴, Astrid Rasmussen¹⁵, George Sarka¹⁶, Daniel Wallace¹⁷, Frederick Vivino¹⁸, Rochelle Zak¹⁹, Nancy Carteron²⁰, R Hal Scofield¹⁵ and Steven Carsons²¹, ¹Washington University in St. Louis, St. Louis, MO, ²University of Kansas Medical Center, Kansas City, KS, ³Sjogren's Foundation, Reston, VA, ⁴Cedars Sinai, Los Angeles, CA, ⁵Brigham and Women's Hospital, Malden, MA, ⁶UT Southwestern Medical Center, Dallas, TX, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Rheumatology Clinic, San Diego, CA, ⁹HonorHealth, Scottsdale, AZ, ¹⁰Johns Hopkins, Reisterstown, MD, ¹¹University of Virginia, Charlottesville, VA, ¹²U.S. Department of Veterans Affairs, Coatesville, PA, ¹³Donald and Barbara Zucker School of Medicine and Hofstra/Northwell, Hempstead, NY, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Cedars-Sinai Medical Center, Laguna Hills, CA, ¹⁷Cedars Sinai Medical Center, Studio City, CA, ¹⁸University of Pennsylvania, Bryn Mawr, PA, ¹⁹UCSF Health, San Francisco, CA, ²⁰University of California, Berkeley & San Francisco, Angwin, CA, ²¹NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Sjögren’s disease is a systemic autoimmune disorder with diverse clinical manifestations affecting multiple organ systems. While dry mouth, dry eyes, fatigue and pain are…
Abstract Number: 1095 • ACR Convergence 2025
Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
dellal azeddine¹, Jean-Guillaume Letarouilly², Jacques Morel³, René-Marc Flipo⁴, Valerie Devauchelle⁵, richette pascal⁶, Philippe Dieude⁷, Hubert Marotte⁸, FELTEN Renaud⁹, LATOURTE Augustin¹⁰, CHEVET Baptiste¹¹, HILLIQUIN Pascal¹², SORDET Christelle⁹, DERNIS mmanuelle¹³, WENDLING Daniel¹⁴, Arsène Mekinian¹⁵, Nathalie BALLANDRAUD¹⁶, Christophe Richez¹⁷, TOURNADRE Anne¹⁸, salmon Jean -Hugues¹⁹, SAILLOT Carine²⁰, kedra joanna²¹, nahon stephane²², LE GOFF Benoit²³, Bruno Fautrel²⁴, Francis BERENBAUM²⁵, David SAADOUN²⁶, PHAM Thao¹⁶ and SELLAM JEREMIE²⁷, ¹GHI LE RAINCY MONTFERMEIL, Montfermeil, France, ²Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, LILLE, Nord-Pas-de-Calais, France, ³CHU and University of Montpellier, Montpellier, France, ⁴Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁵UBO, Brest, France, ⁶Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, ⁷Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ⁸INSERM ¹⁰⁵⁹/University of Saint-Etienne, Saint-Etienne, France, ⁹Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ¹⁰Rheumatology Department, Lariboisiere Hospital, Paris, France, ¹¹CHU BREST, brest, Bretagne, France, ¹²CH SUD FRANCILIEN, PARIS, France, ¹³chu caen, CAEN, Haute-Normandie, France, ¹⁴CHU de Besançon, Besançon, Franche-Comte, France, ¹⁵Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁶CHU MARSEILLE, marseille, Provence-Alpes-Cote d'Azur, France, ¹⁷Bordeaux University Hospital, Bordeaux, France, ¹⁸CHU CLERMONT, CLERMONT, Lorraine, France, ¹⁹CHU REIMS, REIMS, Champagne-Ardenne, France, ²⁰CHU ORLEANS, ORLEANS, Pays de la Loire, France, ²¹Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, ²²GHI LE RAINCY MONTFERMEIL, Montfermeil, Ile-de-France, France, ²³CHU Nantes, Nantes, France, ²⁴Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ²⁵Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ²⁶CHU LA PITIE SALPETRIERE, PARIS, Ile-de-France, France, ²⁷Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France
Background/Purpose: The use of TNFα antagonist is not recommended if the patient have a suspicion or demyelinating diseases (DD) confirmed [1]. There are a few…
Abstract Number: 0601 • ACR Convergence 2025
Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
Ali Ardekani¹, Alain Sanchez-Rodriguez², Mariana González-Treviño³, Jose Meade-Aguilar⁴, Maria O. Valenzuela-Almada⁵, Hannah Langenfeld¹, Larry J. Prokop⁴, Isabel Valenzuela Almada⁶, Gabriel Figueroa-Parra⁷, Nicolás Sánchez Domínguez⁸, Alejandro A. Rabinstein⁴, M. Hassan Murad⁴, Cynthia Crowson⁹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²ABC Medical Center, Ciudad de México, Federal District, Mexico, ³Vanderbilt University Medical Center, Nashville, ⁴Mayo Clinic, Rochester, ⁵Children’s National Medical Center, Washington D.C, ⁶Universidad Panamericana, Ciudad de México, Federal District, Mexico, ⁷Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁸Clínica Alemana de Santiago, Santiago, Chile, ⁹Mayo Clinic, Stewartvillle, MN
Background/Purpose: Posterior reversible encephalopathy syndrome (PRES) is an underrecognized neuroradiologic complication of SLE, characterized by acute neurological symptoms and vasogenic edema on neuroimaging. Its precipitating…
Abstract Number: 0263 • ACR Convergence 2025
A Multicenter Retrospective Case Series of Patients with Susac Syndrome treated with Rituximab
Michelle Benjamin¹, Mattia Wruble Clark², Shamik Bhattacharyya³, Audra Horomanski¹ and Kristin Galetta⁴, ¹Stanford University, Palo Alto, CA, ²Mass General Brigham, Somerville, MA, ³Brigham and Women's Hospital, Malden, MA, ⁴Stanford Medical Center, Palo Alto
Background/Purpose: Susac Syndrome (SuS) is a rare immune-mediated vasculo-occlusive disease characterized by a triad of encephalopathy, hearing loss, and branched retinal artery occlusions. Deficits can…
Abstract Number: 2652 • ACR Convergence 2025
Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility
Zsuzsanna McMahan¹, Srinivas Puttapaka², Livia Casciola-Rosen³, Timothy Kaniecki³, Laura Gutierrez³, Su Hong MIng², Philippa Seika² and Subhash Kulkarni⁴, ¹UT Health Houston, Houston, TX, ²BIDMC/Harvard, Boston, MA, ³Johns Hopkins University, Baltimore, MD, ⁴BIDMC, Boston, MA
Background/Purpose: Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A…
Abstract Number: 0234 • ACR Convergence 2025
Use of Corneal Confocal Microscopy to Assess Small Fiber Neuropathy in Patients with Sarcoidosis
Philip Bucur¹, Kelly Gwathmey², Huzaefah Syed², Aamer Syed², Thomas Iden³, Neha Gupta², Jessica McLaughlin², Jordana Kron², Ryan Canissario², Shanshan Chen¹, Hoda Gad⁴, Rayaz Malik⁴, Sai Patel² and Vaishali Patel², ¹VCU Health, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA, ³Virginia Commonwealth University Medical Center, Richmond, ⁴Weill Cornell Medicine-Qatar, Doha, Qatar
Background/Purpose: Small fiber neuropathy (SFN) is a common complication of sarcoidosis, affecting about one third of patients. The current gold standard for diagnosis combines patient…
Abstract Number: 2541 • ACR Convergence 2025
Development of Severity Classification Criteria for Introduction of Infliximab for Chronic Pogressive Neuro-Behçet’s Disease
Shunsei Hirohata¹, Hirotoshi Kikuchi², Tetsuji Sawada³, Toshihiro Tono⁴, Mitsuhiro Takeno⁵ and Izumi Kawachi⁶, ¹Nobuhara Clinic, Tokyo, Japan, ²Teikyo University School of Medicine, ³-¹²-¹ ????????????¹³⁰⁸, Japan, ³Tokyo Medical University, Tokyo, Japan, ⁴Kitasato University School of Medicine, Kanagawa, Japan, ⁵Nippon Medical School Musashi Kosugi Hospital, Kawasaki, Japan, ⁶Niigata University Graduate School of Medicine and Dental Sciences and Niigata University Brain Institute, Niigata, Japan
Background/Purpose: Chronic progressive neuro-Behçet’s disease (CPNB) is characterized by progressive deterioration leading to disability and death. It has been appreciated that methotrexate (MTX) has beneficial…
Abstract Number: 0184 • ACR Convergence 2025
Neurocognitive Complications of Lupus: A Multidisciplinary Program Model for Advanced Diagnostics, Management, and Clinical Research
Douglas Wilcox¹, Matthew Baum², Sophie Lebiedz², John Sullivan², Margaret Naclerio², Jonathan Zurawski², Bonnie Glanz², Rohit Bakshi², Tanuja Chitnis², Shamik Bhattacharyya³ and Karen H. Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Malden, MA, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Neurological symptoms in lupus are common and occur in the majority of patients with SLE. Although neuropsychiatric lupus (NPSLE) can involve the entire nervous…
Abstract Number: 2515 • ACR Convergence 2025
The Association Between Neurologic Involvement and Cumulative Damage in ANCA-Associated Vasculitis
Ruoning Ni¹, Jessica L. Bloom², Kaci Pickett-Nairne², Lori Silveira³, Chao Zhang⁴, David Cuthbertson⁵, Thomas corbridge⁶, Nader Khalidi⁷, Curry Koening⁸, Carol McAlear⁹, Paul Monach¹⁰, Larry Moreland¹¹, Christian Pagnoux¹², Rennie Rhee⁹, Philip Seo¹³, Jared Silver⁶, Ulrich Specks¹⁴, Kenneth Warrington¹⁴, Michael Wechsler¹⁵, Carol Langford¹⁶, Peter Merkel⁹ and Rula Hajj-Ali¹, ¹Cleveland Clinic, Cleveland, ²University of Colorado, Denver, ³University of Colorado, Aurora, CO, ⁴Cleveland Clinic, Cleveland Heights, OH, ⁵University of South Florida, Tampa, ⁶US Medical Affairs Respiratory GSK, Durham, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁸University of Texas Dell Medical School, Austin, TX, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹University of Colorado, Denver, CO, ¹²Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴Mayo Clinic, Rochester, MN, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶Cleveland Clinic, Moreland Hills, OH
Background/Purpose: Neurologic involvement (NI) is common in ANCA-associated vasculitis (AAV) and often irreversible. It is unknown whether patients with AAV and NI accumulate more damage…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].